Neurological conditions are complex and require a high level of expertise and sensitivity, making them an juicy area for medical affairs teams. How do the challenges shape the MA role in this space and how is the landscape evolving?

As the pharmaceutical industry transitions from the Trump to the Biden era, what regulatory changes can be expected and how will a new approach to healthcare policy affect the sector? 

Addressing global access to medicine, particularly in LMICs, poses a significant challenge. As COVID-19 vaccines are distributed, how can the pharmaceutical industry ensure they reach vulnerable populations in these countries while protecting patent rights? 

While the pandemic has placed pressure and strain on all members of society, it has had a profound and lesser acknowledged effect on unpaid and family carers. What has been the impact of COVID-19 on those looking after loved ones and how can we better support them in the future?

How is the data revolution going to impact the marketing and medical functions?

Some thoughts about how the Rare Disease Act impacted pharma and if it needs further updating after almost 20 years.

Monica Shaw, Executive Vice President, Region EUROPE Plus, LEO Pharma, speaks with GOLD about digital transformation in healthcare

While pharmaceutical marketers used to rely heavily on push marketing, since the pandemic, a call to move to pull advertising has prevailed. How can pharma further engage the medical affairs function to draw in doctors with tailored, scientific content that is targeted and trustworthy?